Clinical trial Recruiting at 27 sites Observational

Observational study on the effectiveness and safety of SKYTROFA for growth hormone deficiency

Official title: A US Multi-center, Prospective, Non-interventional, Long Term, Effectiveness and Safety Study of Patients Treated With SKYTROFA (Lonapegsomatropin)

Run by Ascendis Pharma A/S · NCT05820672 · Data updated 2026-11-12

This study is testing how well and safely SKYTROFA works for people with growth hormone deficiency by looking at their experiences during regular treatment.

More Growth Hormone Deficiency trials

Quick facts

Study typeObservational
SexAll
Enrollment900 (estimated)
SponsorAscendis Pharma A/S
Industry-sponsored
Locations27 sites (Phoenix, Arizona and 26 other locations)
StatusRecruiting
StartedMarch 20, 2023
Main results expectedMarch 2033
Study endsMarch 2033
Registry record updatedApril 21, 2026
Trial IDNCT05820672 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are patients currently being treated with SKYTROFA and managed clinically in the USA.

Probably not a fit

Patients participating in any interventional clinical study will not benefit from this observational study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to gather evidence on the long-term effectiveness and safety of SKYTROFA (lonapegsomatropin) in patients diagnosed with growth hormone deficiency. Patients will receive treatment as per routine clinical practice without any additional visits or tests beyond standard care, except for specific clinical outcome assessments. The study will focus on real-world data to better understand the treatment's impact over time.

Why it matters

Potential benefit: If successful, this study could provide valuable insights into the long-term safety and effectiveness of SKYTROFA for patients with growth hormone deficiency.

How similar studies have gone: Other studies have shown success in gathering real-world evidence for similar treatments, making this approach both relevant and valuable.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patients who are on treatment with SKYTROFA (lonapegsomatropin)
* Patients being clinically managed in USA
* Patients with an appropriate written informed consent/assent as applicable for the age of the patient

Exclusion Criteria:

* Patients participating in any interventional clinical study

Where it's running

  • Ascendis Investigational Site
    Phoenix, Arizona, United States
    Recruiting
  • Ascendis Investigational Site
    Orange, California, United States
    Recruiting
  • Ascendis Investigational Site
    Sacramento, California, United States
    Recruiting
  • Ascendis Investigational Site
    San Francisco, California, United States
    Recruiting
  • Ascendis Pharma Investigational Site
    Centennial, Colorado, United States
    Recruiting
  • Ascendis Investigational Site
    Washington D.C., District of Columbia, United States
    Recruiting
Show 21 more locations
  • Ascendis Investigational Site
    Orlando, Florida, United States
    Recruiting
  • Ascendis Investigational Site
    Orlando, Florida, United States
    Recruiting
  • Ascendis Investigational Site
    Tampa, Florida, United States
    Recruiting
  • Ascendis Investigational Site
    Sandy Springs, Georgia, United States
    Recruiting
  • Ascendis Investigational Site
    Boise, Idaho, United States
    Recruiting
  • Ascendis Investigational Site
    Indianapolis, Indiana, United States
    Recruiting
  • Ascendis Investigational Site
    Iowa City, Iowa, United States
    Recruiting
  • Ascendis Investigational Site
    Louisville, Kentucky, United States
    Recruiting
  • Ascendis Investigational Site
    Minneapolis, Minnesota, United States
    Recruiting
  • Ascendis Investigational Site
    Las Vegas, Nevada, United States
    Recruiting
  • Ascendis Investigational Site
    Lebanon, New Hampshire, United States
    Recruiting
  • Ascendis Investigational Site
    Manchester, New Hampshire, United States
    Recruiting
  • Ascendis Investigational Site
    Morristown, New Jersey, United States
    Recruiting
  • Ascendis Investigational Site
    New Hyde Park, New York, United States
    Recruiting
  • Ascendis Investigational Site
    Cincinnati, Ohio, United States
    Recruiting
  • Ascendis Investigational Site
    Portland, Oregon, United States
    Recruiting
  • Ascendis Investigational Site
    Columbia, South Carolina, United States
    Recruiting
  • Ascendis Investigational Site
    Dallas, Texas, United States
    Recruiting
  • Ascendis Investigational Site
    El Paso, Texas, United States
    Recruiting
  • Ascendis Investigational Site
    Norfolk, Virginia, United States
    Recruiting
  • Ascendis Investigational Site
    Seattle, Washington, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.